louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01077947: Value of Functional Anesthetic and Provocative Discography in the Surgical Treatment of Discogenic Pain
Official title: Comparing the Value of Functional Anesthetic and Provocative Discography in the Surgical Treatment of Discogenic Pain
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Discogenic Pain
Low Back Pain
Keywords: low back pain
spinal fusion
Primarily axial low back pain
Lead sponsor: Northwestern University
Sponsor class: OTHER
Collaborators: name: Medtronic Spine LLC
First posted: 2010-03-01
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Although discography and spinal imaging techniques, either alone or in combination, are commonly used to diagnose discogenic pain, their exact role in predicting surgical results are poorly defined. Our aim in this study is to compare the ability of Functional anesthetic discography (FAD), and Provocative Discography (PD) to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition. Patients with discogenic pain have better outcomes if the disc levels for the fusion surgery are identified by using FAD compared to similar disc level identification by PD.


Eligibility criteria: Inclusion Criteria:

1. Age between 21 to 65 years.
2. Symptoms of at least 6 months duration.
3. Primarily axial low back pain.
4. At least 6 months of conservative treatment, including, physical therapy, injections, chiropractic etc.
5. Patients with overall pain scores of greater than 6/10 (NRS).
6. Recent (within the past 6 months) lumbar spine MRI showing: disc desiccation and loss of disc height of at least one disc level.

Exclusion Criteria:

1. History of previous spine surgery.
2. MRI changes at more than two disc levels on the recent (within the past 6 months) lumbar spine MRI.
3. Clinical or radiological evidence of significant:

   1. Disc herniation
   2. Spinal Stenosis
   3. Spinal Deformity
   4. Spondylolisthesis
   5. Spinal instability or pars-defect
   6. Facet Syndrome
   7. Sacroiliac Joint Dysfunction
   8. Myofascial Pain Syndrome
   9. Fibromyalgia
4. Current issues of:

   1. Litigation
   2. Disability
   3. Drug addiction or substance abuse
   4. Chronic pain medication abuse
5. Current diagnosis of and medication use for unstable anxiety, depression, and/or behavioral disorders.

Primary outcomes:
measure: Pain
timeFrame: One Year
Secondary outcomes:
measure: Physical functioning
timeFrame: One Year
measure: Quality of Life
timeFrame: One Year
measure: Patient Satisfaction
timeFrame: One Year
Other outcomes:
Locations:
Study officials:
affiliation: Department of Anesthesiology, Northwestern University, Feinberg School of Medicine
name: Khalid Malik, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02765347: The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM
Official title: The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM: A Randomized, Cross-over, Prospective Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 1
Lead sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2016-05-06
Enrollment: 30
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The investigators intends to carry out a randomized, cross-over, prospective study which will last 48 weeks in youth with T1DM followed up by the center. The purpose is to observe the effects of metformin on glycemic control and insulin sensitivity in adolescents with T1DM based on insulin therapy by using 72h CGMS and hyperinsulinemic euglycemic clamps.


Eligibility criteria: Inclusion Criteria:

1. Type 1 diabetes mellitus;
2. Age≥12 yr;
3. Tanner sexual maturation rating 2-5;
4. HbA1c levels: 7.5%-10%;
5. MDI or CSII ≥6 months;
6. Insulin dose ≥ 0.8U/kg before the enrollment，and the dosage is stable at least \>1 month（dosage change\<10%）.

Exclusion Criteria:

1. Serious acute and chronic complications associated with diabetes;
2. Repeated and serious hypoglycemia episodes repeatedly;
3. Hepatic function damage (ALT≥2.5 times higher than the upper limit of the normal accepted range);
4. Moderate to advanced renal impairment (calculated according to MDRD equation: eGFR\<60ml/min/1.73m2);
5. Clinically significant heart attacks: myocardial infarction, arrhythmia，II-III°AVB，unstable angina，decompensated HF（NYHA III\~IV;
6. Female patients who have a sex life and are not willing to use contraceptive methods;
7. Pregnancy.

Primary outcomes:
measure: HbA1c
timeFrame: half one year
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: The Third Affliated Hospital of Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Associated professor
name: Wen Xu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01054547: Topical Formulations of Liposomal Local Anesthetics
Official title: Local Anesthetic Activity of Liposomal Formulations in Dentistry
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Administration, Topical Drug
Administration, Topical
Anesthetic Drugs
Keywords: topical anesthetic
liposomal ropivacaine
dentistry
Lead sponsor: University of Campinas, Brazil
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2010-01-22
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This blinded cross-over study aim to evaluate the efficacy of topical liposome-encapsulated ropivacaine formulations.

Detailed description: This blinded cross-over study aim to evaluate the efficacy of topical liposome-encapsulated 1 and 2% ropivacaine gel formulations.

Eligibility criteria: Inclusion Criteria:

* Healthy

Exclusion Criteria:

* Volunteers were free from cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal and haematological diseases, psychiatric disorders and allergy to local anesthetics

Primary outcomes:
measure: After topical application of the local anesthetic formulations at the oral mucosa, their influence on pulpal response was assessed by an electrical pulp tester.
timeFrame: 10 minutes
Secondary outcomes:
measure: The efficacy of the topical anesthetics was measured after a simulation of a local anesthesia in the application site (insertion of a 30 gauge needle until periosteum contact).
timeFrame: 10 seconds after removal of topical formulation
Other outcomes:
Locations:
city: Piracicaba
country: Brazil
facility: Piracicaba Dental School
state: Sao Paulo
Study officials:
References:
citation: Franz-Montan M, de Paula E, Groppo FC, Silva AL, Ranali J, Volpato MC. Liposome-encapsulated ropivacaine for intraoral topical anesthesia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Dec;110(6):800-4. doi: 10.1016/j.tripleo.2010.07.005.
citation: Franz-Montan M, de Paula E, Groppo FC, Silva AL, Ranali J, Volpato MC. Liposomal delivery system for topical anaesthesia of the palatal mucosa. Br J Oral Maxillofac Surg. 2012 Jan;50(1):60-4. doi: 10.1016/j.bjoms.2010.10.018. Epub 2010 Nov 23.
Clinical trial NCT04894747: Mycoprotein and Pea Protein Blend and Muscle Protein Synthetic Response
Official title: Comparing Postprandial Muscle Protein Synthesis Rates Following the Consumption of Mycoprotein, Pea Protein and a Mycoprotein/Pea Protein Blend in Resistance Trained Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Muscle Protein Synthesis
Lead sponsor: University of Exeter
Sponsor class: OTHER
Collaborators: name: Quorn
First posted: 2021-05-20
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Dietary protein is vital for the preservation of health and optimal adaptation to training. Plant proteins are considered inferior to animal proteins with respect to their ability to stimulate an acute muscle building response and therefore support long-term muscle reconditioning. Pea protein is a highly commercially available plant proteins source (available as supplements, food ingredients etc.), yet there is no research investigating its ability to stimulate a muscle building response. The investigators aim to assess the effect of consuming pea protein on muscle protein synthesis rates and compare these results to mycoprotein, a source known to elicit a robust anabolic response.

Pea protein is lower in some of the essential amino acids, namely methionine, which could mean it is less effective compared with mycoprotein which has a more complete amino acid profile. So in addition to comparing pea with mycoprotein, the investigators also want to compare to a blend of pea and mycoprotein to see if replenishing the amino acid content in pea 'rescues' the anabolic response.


Eligibility criteria: Inclusion Criteria:

* BMI between 18 and 30
* Resistance trained

Exclusion Criteria:

* Any metabolic impairment
* Smoking
* Use of over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices).
* A personal family history of epilepsy, seizures or schizophrenia.
* Allergic to Quorn/mycoprotein/edible fungi/environmental mould products.
* Any motor disorder.

Primary outcomes:
measure: Muscle protein synthesis
timeFrame: 8.5 hours
Secondary outcomes:
measure: Plasma amino acid kinetics
timeFrame: 8.5 hours
measure: Serum insulin concentrations
timeFrame: 8.5 hours
measure: Translocation of mTOR via immunohistochemistry
timeFrame: 8.5 hours
measure: mTOR phosphorylation via ATP kinase assay
timeFrame: 8.5 hours
Other outcomes:
Locations:
city: Exeter
country: United Kingdom
facility: University of Exeter
Study officials:
References:
Clinical trial NCT01356147: Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)
Official title: Pilot Study of Dornase Alfa (Pulmozyme) Therapy for Acquired Ventilator Associated Infection in Preterm and Late Preterm Infants in the Neonatal Intensive Care Unit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pulmonary Infections
Keywords: ventilator associated pulmonary infections
Lead sponsor: Georgetown University
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
First posted: 2011-05-19
Enrollment: 11
Sex: ALL
Minimum age (years): 7
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the effect of Dornase alfa on preterm and late preterm neonates with ventilator associated pulmonary infections. Dornase alfa has been effective in the treatment of pulmonary infections in patients with cystic fibrosis by aiding mucus clearance. The bacteria causing pulmonary infections in cystic fibrosis patients is similar to those infecting preterm infants. The investigators expect that dornase alfa therapy will improve recovery from ventilator associated pulmonary infections in preterm infants.


Eligibility criteria: Inclusion Criteria:

* infants less than 38 weeks gestation and over 7 days of age
* infants with a ventilator associated pulmonary infection, defined as intubated infants who have moderate to heavy White Blood Cells (WBCs) on tracheal aspirate, organisms on tracheal aspirate gram stain, a positive endotracheal tube culture, a chest x-ray with infiltrate, consolidation or atelectasis, an increase in oxygen (FiO2) requirement and whom the clinical team decides to treat with systemic antibiotic therapy

Exclusion Criteria:

* Extremely ill infants not expected to survive
* Critically ill infants requiring high frequency ventilation
* Infants with congenital pneumonia
* Infants with congenital malformations of the respiratory system (e.g. Congenital diaphragmatic hernia, cystic adenomatoid malformation or tracheo-esophageal fistula) Cyanotic congenital heart disease, chromosomal abnormalities and infants with a positive newborn screen for cystic fibrosis

Primary outcomes:
measure: Percent Reduction in Oxygen Requirement From Baseline
timeFrame: First week of treatment or extubation
Secondary outcomes:
measure: Elimination of White Blood Cells and Bacteria From Tracheal Aspirate
timeFrame: During first week of treatment or until extubation whichever is earlier
measure: Number of Infants Requiring Ventilator Support
timeFrame: 7 days
Other outcomes:
Locations:
city: Washington
country: United States
facility: Georgetown University Hospital NICU
state: District of Columbia
city: Washington
country: United States
facility: Georgetown University Hospital
state: District of Columbia
Study officials:
References:
Clinical trial NCT01867047: ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients
Official title: Effects of Angiotensin Converting Enzyme Inhibitors on Total Hip and Knee Arthroplasty Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Adverse Effects of Angiotensin-converting-enzyme Inhibitors
Hypotension
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2013-06-03
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine the effects of Angiotension Converting Enzyme Inhibitors (ACE-I) during surgery and in the immediate postoperative period for patients undergoing elective total hip or knee arthroplasty.


Eligibility criteria: Inclusion Criteria:

* Patients electing to undergo primary or revision total hip or knee arthroplasty
* Currently taking an ACE-I

Exclusion Criteria:

* Trauma patients
* Immunosuppressed patients (HIV/AIDS, organ transplant recipients, chemotherapy patients, chronic steroid use)
* Patients with history of severe hypertension related illness such as hypertension associated with stroke or myocardial infarction
* Patients in who continuation of their ACE-I is expressly mandated by their prescribing physician

Primary outcomes:
measure: Number of Participants With Mild Hypotension
timeFrame: From baseline to discharge from hospital (approximately 5 days)
measure: Number of Participants With Severe Hypotension
timeFrame: From baseline to discharge from hospital (approximately 5 days)
measure: Number of Participants Given Vasopressors
timeFrame: Discharge from hospital (approximately 5 days)
Secondary outcomes:
measure: Number of Participants Transferred to Intensive Care Unit (ICU)
timeFrame: Discharge from hospital (approximately 5 days)
measure: Number of Participants That Received Allogeneic Blood
timeFrame: Discharge from hospital (approximately 5 days)
measure: Number of Participants With Acute Kidney Injury
timeFrame: Discharge from hospital (approximately 5 days)
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
affiliation: Duke University
name: Michael Bolognesi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02744547: Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C
Official title: Effect of Spirulina on Serum Hyaluronic Acid as a Marker for Liver Fibrosis in Beta Thalassemic Children With Hepatitis C
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Beta Thalassemia Major
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2016-04-20
Enrollment: 60
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Thalassemics can develop liver fibrosis because of iron overload and hepatitis C infection. The latter is the main risk factor for liver fibrosis in transfusion dependent thalassemics. Excess liver iron is clearly recognized as a co factor for the development of advanced fibrosis in patients with hepatitis virus C infection. Hyaluronic acid serum levels correlate with histological stages of liver fibrosis in hepatitis C patients, so it has a good diagnostic accuracy as a non invasive assessment of fibrosis and cirrhosis.there is evidence that suggests Spirulina may help to protect against liver damage, cirrhosis and liver failure in those with chronic liver disease.


Eligibility criteria: Inclusion Criteria:

* multitransfused beta thalassemic children with and without super added hepatitis C virus (HCV) infection diagnosed by serological detection of HCV antibodies and HCV RNA by polymerase chain reaction.

Exclusion Criteria:

* liver decompensation child younger than 3 years patients with hepatitis B infection

Primary outcomes:
measure: serum hyaluronic acid levels
timeFrame: 3 months
Secondary outcomes:
measure: liver function tests
timeFrame: 3 months
measure: aspartate aminotransferase to platelet ratio index (APRI)
timeFrame: 3 months
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Faculty of Medicine- Tanta University
state: Gharbia
Study officials:
References:
Clinical trial NCT01396798: Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E.
Official title: Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in a High Prevalent Setting: the Paediatric A&E.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Community-Acquired Infections
Respiratory Tract Infections
Sepsis
Urinary Tract Infections
Meningitis
Gastroenteritis
Keywords: serious infections
meningitis
Lead sponsor: KU Leuven
Sponsor class: OTHER
First posted: 2011-07-19
Enrollment: 1500
Sex: ALL
Minimum age (years): 1
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children aged 1 month to 16 years, attending the A\&E department of the UZLeuven Hospital with an acute illness episode of maximum 5 days

Brief summary: Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Acutely Ill Children in a High Prevalent Setting: The Paediatric Accidents \& Emergencies through prospective observational data collection concerning specific items from the clinical and technical examination in diagnosing serious infections, such as meningitis, sepsis, pneumonia, pyelonephritis, bronchiolitis with hypoxia. Eventually we will attempt to validate a vital signs and symptoms rule derived from multiple low to high prevalent settings of acutely ill children.


Eligibility criteria: Inclusion Criteria:

* Children aged 1 month to 16 years
* Acute illness episode of maximum 5 days

Exclusion Criteria:

* recent trauma
* neurological conditions
* intoxication
* psychiatric of behavioural disorders without a somatic cause
* acute exacerbation of a chronic condition (asthma, known immunodeficiency, diabetes, cystic fibrosis, etc)

Primary outcomes:
measure: serious infections: meningitis, sepsis, pneumonia, pyelonephritis, osteomyelitis and cellulitis, gastroenteritis with sever dehydration, complicated urinary tract infection and complicated viral airway infection with hypoxia.
timeFrame: within 24 hours after assessment
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: Dienst Algemene Kindergeneeskunde, Universitaire Ziekenhuizen Leuven
state: Vlaams-Brabant
Study officials:
affiliation: KU Leuven
name: Jan YJ Verbakel, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Van den Bruel A, Haj-Hassan T, Thompson M, Buntinx F, Mant D; European Research Network on Recognising Serious Infection investigators. Diagnostic value of clinical features at presentation to identify serious infection in children in developed countries: a systematic review. Lancet. 2010 Mar 6;375(9717):834-45. doi: 10.1016/S0140-6736(09)62000-6. Epub 2010 Feb 2.
citation: Van den Bruel A, Aertgeerts B, Bruyninckx R, Aerts M, Buntinx F. Signs and symptoms for diagnosis of serious infections in children: a prospective study in primary care. Br J Gen Pract. 2007 Jul;57(540):538-46.
Clinical trial NCT00180245: Tumor Metabolism of Head and Neck Cancer in Patients Who Underwent Radiation Therapy Measured With F-18-FDG-PET
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Head and Neck Cancer
Keywords: Radiation therapy
F-18-FDG
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study includes consecutive patients from the Department of Radiooncology with head and neck cancer (HNC) intended for a curative chemoradiotherapy.

Brief summary: The purpose of the study is to describe the regional and global FDG-kinetics in head and neck cancer during percutaneous radiation therapy.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed head and neck cancer not curable by surgery
* Karnofsky \> 70%
* Tumor volume and localization allow curative radiotherapy
* Written consent

Exclusion Criteria:

* Metastases
* Earlier radiotherapy of head or neck
* Pregnancy
* Secondary malignancy excluding dermal carcinoma T1 and Tis-carcinoma of cervix uteri
* Psychiatric impairment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: Department of Nuclear Medicine
Study officials:
affiliation: Department of Nuclear Medicine
name: Joerg Kotzerke, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01161745: PD-1/PD-L1 Pathway Study on Septic Patients
Official title: PD-1/PD-L1 Pathway in T Lymphocyte Apoptosis and Monocyte Dysfunction in Septic Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sepsis
Keywords: sepsis
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
Collaborators: name: National Natural Science Foundation of China
First posted: 2010-07-14
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who develop sepsis

Brief summary: The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.

Detailed description: First, we will detect PD-L1 expression on PBMC of septic patients and healthy controls.

Second, blockade of PD-1/PD-L1 pathway in vitro and stimulate with some biomolecules and then analyze the PBMC function and apoptosis by flow cytometry.

Then, compare with healthy controls and find the differences.

Eligibility criteria: Inclusion Criteria:

* patients who develop sepsis

Exclusion Criteria:

* patients with cirrhosis or renal dysfunction
* patients with dyscrasia
* patients with autoimmunity diseases
* patients with severe cardiac and pulmonary diseases
* patients with hematological diseases
* patients with diabetes mellitus
* patients with malignant tumors

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Changhai Hospital, the Second Military Medical University
name: Xiao-ming Deng, doctor
role: PRINCIPAL_INVESTIGATOR
References: